Fig 1: ZDHHC21 mutation inducing cognitive decline and aberrant palmitoylation of APP and FYN in mice. A The Morris water maze test of WT and ZDHHC21T209S/T209S mice (9 months old), including latency to platform (left), number of platform crosses (middle), and time in the target quadrant (right). B and C Immunoblot showing co-immunoprecipitation of ZDHHC21 with APP (B) or FYN (C) in the WT and p.T209S hippocampi (9 months old). D Immunofluorescence of ZDHHC21, FYN, and DAPI in the WT and p.T209S hippocampi (6 months old). E and F Representative immunoblot (up) and quantification (down) of APP (E) or FYN (F) palmitoylation levels in WT and ZDHHC21T209S/T209S hippocampi (6 months old). G Representative immunoblot (up) and quantification (down) of FYN levels in hippocampal membrane proteins in WT and ZDHHC21.T209S/T209S mice (6 months old). Values are expressed as means ± SEMs of 8 to 11 (A), 3 (B to D), or 4 (E to G) mice per group. Data in B–G were based on three independent experiments. All mouse groups contained mice of both sexes. Data were analyzed via two-way ANOVA with Tukey’s multiple-comparisons test (A: left), unpaired two-tailed Student’s t-tests (A: middle and right, G), and paired two-tailed Student’s t-test (E and F). *P < 0.05, **P < 0.01. Scale bar, 20 μm (D)
Fig 2: Treatment with rhHSP70 or bimoclomol increases the ratio of active-to-inactive phosphorylated forms of Fyn kinase in the cerebellum of Npc1−/− mice. Representative Western blots of total Fyn and its phosphorylated active (pY418) and inactive (pY531) forms following immunoprecipitation of Fyn kinase in a) cerebellar samples from Npc1+/+ comparators or Npc1−/− mice following treatment with PBS (vehicle), rhHSP70, or bimoclomol (bim) at P35. b) Quantification of the relative levels of the phosphorylated active and inactive forms of Fyn kinase as well as the ratio of pY418:pY531. Data are presented as the mean + SD of three independent experiments using n = 3 mice per treatment group. Effects of treatments were analysed using a one-way ANOVA on log-transformed values and multiplicity was adjusted using Dunnett's method (n = 2 comparisons; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).
Fig 3: Bimoclomol mediated improvements in cerebellar weight and myelination are blocked by saracatinib co-treatment. Representative Western blots & relative expression of a) cerebellar MBP (n = 4/group), b) cerebellar Fyn (n = 4/group) and c) cerebellar wet weights (Npc1+/+ + vehicle: n = 6; Npc1+/+ + saracatinib: n = 6; Npc1+/+ + bimoclomol (Bim): n = 5; Npc1+/+ + bim/sara: n = 5; Npc1−/− + vehicle: n = 6; Npc1−/− + saracatinib: n = 5; Npc1−/− + bimoclomol (Bim): n = 5; Npc1−/− + bim/sara: n = 6) in Npc1+/+ or Npc1−/− mice at P35 following treatment with vehicle, 10 mg/kg/day of either saracatinib or bimoclomol, or a combination of bimoclomol/saracatinib (bim/sara). Data are presented as mean + SD. Effects of treatments were analysed using a two-way ANOVA on log-transformed values. Multiplicity was adjusted using Dunnett's method (n = 3 comparisons; ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001, ∗∗∗∗p < 0.0001).
Fig 4: COX, PAS, and NADH-TR staining of the TA muscles of tail-suspended mice(A) COX staining demonstrates a marked increase in the number of mitochondria in the TA muscles of WT mice subjected to TS (a), whereas no significant differences are observed in the muscles of Fyn-null mice subjected to TS (b).(B) The level of perinuclear and cytoplasmic glycogen, a known substrate of autophagy, is increased in the muscles of WT mice subjected to TS (a), indicating the inhibition of autophagy, which is not observed in the muscles of Fyn-null mice subjected to TS (b).(C) NADH-TR staining demonstrates a decrease in the cross-sectional area of type 2 muscle fiber (light-stained fibers) size in the TA muscles of WT mice subjected to TS (a), whereas no significant differences are observed in the muscles of Fyn-null mice subjected to TS (b). See also Figure S5. Scale bars in the tissue images represent the lengths defined in each figure.
Fig 5: Muscular autophagy in the tail-suspension secondary sarcopenia model(A) Selective muscle sizes from control and TS mice (n = 6 per group). Data are expressed as mean ± SEM. ∗∗∗p < 0.005 vs. control.(B) mRNA expression levels of atrogin-1 and MuRF-1, relative to β-actin, in the gastrocnemius muscles of TS mice (n = 3). Data are expressed as mean ± SEM. ∗∗∗p < 0.005 vs. control.(C) Representative immunoblots from three independent experiments with gastrocnemius muscles of control and TS mice, developed using the indicated antibodies. Signal quantification of the protein expression levels of Fyn, normalized to GAPDH (n = 3). Data are shown as mean ± SEM. ∗∗∗p < 0.005 vs. control. Signal quantification of the expression levels of total STAT3, normalized to GAPDH, and phosphoY705-STAT3, normalized with total STAT3 (n = 3). Data are shown as mean ± SEM. ∗∗∗p < 0.005 vs. control.(D) Representative H&E staining of control and TS mice. See also Figure S2.(E) Representative p62 immunofluorescence visualized in control and TS mice. Proportion of p62-positive myocytes in control and TS mice (n = 3). Data are expressed as mean ± SEM. ∗p < 0.05 vs. control.(F) Three-month-old control and TS mice were treated with either vehicle (as control) or 0.4 mg/kg/day colchicine for two days. Immunoblots of the TA muscle were obtained using the indicated antibodies. Representative immunoblots of three independent experiments. Signal quantification of the expression levels of LC3-II, normalized with GAPDH levels (n = 3). Data are expressed as mean ± SEM. ∗∗∗p < 0.005 vs. control. The Mann–Whitney U test was used for statistical comparison. The bars on each column show standard error of the mean. Scale bars in the tissue images represent the lengths defined in each figure. Abbreviations: TA, tibialis anterior; TS, tail suspension; SEM, standard error of the mean; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; STAT3, signal transducer and activator of transcription 3; C, control; Col, colchicine.
Supplier Page from Abcam for Anti-Fyn antibody [FYN-01]